ReviewMolecules (Basel, Switzerland)2019
Aptamers Chemistry: Chemical Modifications and Conjugation Strategies.
Review in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 164 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
164 citing papers in PubMed, 384 citations in OpenAlex.
- Lipid nanoparticles with aptamers enable targeted mRNA delivery to CD4⁺ T cells.Drug delivery · 2026Article
- Aptamer targeting proprotein convertase subtilisin/kexin type 9:Research in pharmaceutical sciences · 2026Article
- Advances in Aptamer Drug Delivery Systems for Treatment of Glioblastoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Molecular Engineering of Aptamers for Glioblastoma Therapy: From Simple Antagonists to AI-Driven Approaches, a Narrative Review.International journal of molecular sciences · 2026Review
- Selection and validation of novel DNA aptamer panel co-specific toMolecular therapy. Nucleic acids · 2026Article
- Article
- Targeted Strategies for Treatment of Colorectal Cancer: Exploring the Use of Aptamers and Gold Nanoparticles.Molecules (Basel, Switzerland) · 2026Review
- In Vivo Continuous Biosensing: Design Considerations and Emerging Technologies.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Nanoparticles-assisted SELEX strategies for aptamer screening: a comprehensive review.Mikrochimica acta · 2026Review
- Beyond Fungitoxicity: Recent Achievements in Targeted Fungicide Discovery.Journal of fungi (Basel, Switzerland) · 2026Review
- His-Tag-Aptamer-Liposome-Conjugates as a Multipurpose Tool for Recombinant Protein Screening and Protein-Based Bioassays.Analytical chemistry · 2026Article
- RNA Aptamers and Epitranscriptomics: Charting Unexplored Territories in RNA Biology.Molecular diagnosis & therapy · 2026Review
- Aptamer-Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap.Small science · 2026Article
- Deconstructing the RAGE signaling maze: the molecular key to opening a new dimension of ovarian anti-aging.Experimental & molecular medicine · 2026Review
- Macroscopic polarimetric discrimination and quantification of antiangiogenic effect of AGRO aptamer and GK1 peptide in a preclinical melanoma model.Scientific reports · 2026Article
- Exploiting the role of milk extracellular vesicles: a comprehensive analysis on isolation methods, characterization, surface modifications, and their therapeutic applications.Journal of nanobiotechnology · 2026Review
- miRNA-driven cancer cell plasticity, tolerance and therapy resistance: lessons from melanoma.Molecular cancer · 2026Review
- Aptamer-liposome targeted nanotherapeutics for cancer therapy: Bibliometric analysis, recent developments and future perspectives.Materials today. Bio · 2026Review
- Aptamers in Osteoimmune Regulation: Scientific Rationale, Emerging Evidence and Translational Challenges.International journal of nanomedicine · 2026Review
- Aptamers and aptamer-drug conjugates as synthetic immune modulators for cancer immunotherapy.Frontiers in immunology · 2026Review
104 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soon after they were first described in 1990, aptamers were largely recognized as a new class of biological ligands that can rival antibodies in various analytical, diagnostic, and therapeutic applications. Aptamers are short single-stranded RNA or DNA oligonucleotides capable of folding into complex 3D structures, enabling them to bind to a large variety of targets ranging from small ions to an entire organism. Their high binding specificity and affinity make them comparable to antibodies, but they are superior regarding a longer shelf life, simple production and chemical modification, in addition to low toxicity and immunogenicity. In the past three decades, aptamers have been used in a plethora of therapeutics and drug delivery systems that involve innovative delivery mechanisms and carrying various types of drug cargos. However, the successful translation of aptamer research from bench to bedside has been challenged by several limitations that slow down the realization of promising aptamer applications as therapeutics at the clinical level. The main limitations include the susceptibility to degradation by nucleases, fast renal clearance, low thermal stability, and the limited functional group diversity. The solution to overcome such limitations lies in the chemistry of aptamers. The current review will focus on the recent arts of aptamer chemistry that have been evolved to refine the pharmacological properties of aptamers. Moreover, this review will analyze the advantages and disadvantages of such chemical modifications and how they impact the pharmacological properties of aptamers. Finally, this review will summarize the conjugation strategies of aptamers to nanocarriers for developing targeted drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.